AKT1 and prostate cancer: In addition to PI3K/AKT and RAS/ERK signaling, the new evidence has emerged that connected signaling by GPCR/PKA module to prostate cancer progression and therapy resistance via inhibition of apoptosis in tumor epithelial cells and stem cells, and increased angiogenesis [21,196,197,198].